Mirati Therapeutics secures UK approval for KRAZATI in advanced NSCLC
Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its KRAZATI (adagrasib) monotherapy. This approval marks a pivotal milestone for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who present the KRASG12C mutation and have not responded to prior therapies.
Targeted NSCLC Therapy KRAZATI Cleared for Use in UK
KRAZATI stands out as a targeted treatment, specifically tailored to tackle the KRASG12C mutation, known for its rapid protein regeneration. The drug’s ability to penetrate the central nervous system (CNS) is crucial, as CNS metastases are common in advanced NSCLC and are associated with a challenging prognosis.
Expert Opinions and Clinical Trial Insights
“MHRA’s authorization of KRAZATI is a key advancement for patients and healthcare professionals managing advanced NSCLC with the KRASG12C mutation,” stated Dr. Alan Sandler, Chief Medical Officer at Mirati Therapeutics. In support, Dr. Shobhit Baijal from The University Hospital Birmingham points to the necessity for more targeted treatments, given the mutation’s prevalence in NSCLC patients and the current scarcity of options.
The approval of KRAZATI is bolstered by findings from the KRYSTAL-1 clinical trial, an open-label, Phase 1/2 study which evaluates the efficacy of adagrasib in treating advanced solid tumors with the KRASG12C mutation, administered alone or in combination with other treatments.